Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

azatoxin

Known as: 1H,6H-3-one-5,4,11,11a-tetrahydro-5-(3,5-dimethoxy-4-hydroxyphenyl)oxazolo(3',4'-1,6)pyrido(3,4-b)indole 
 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

IndolesTopoisomerase II Inhibitors

Narrower (2)

NSC 640737NSC 640737-M

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Lignans and neolignans as lead compounds
Many lignans and neolignans have served as lead compounds for the development of new drugs. Perhaps the best known example is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
Fluoroquinolones are broad-spectrum antimicrobial agents that target type II topoisomerases. Many fluoroquinolones are highly… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
The synthesis of amino-acid functionalized beta-carbolines as topoisomerase II inhibitors.
The synthesis and biological activity of amino acid functionalized beta-carboline derivatives, which are structurally related to… Expand
Is this relevant?
1999
1999
Molecular Analysis of Yeast and Human Type II Topoisomerases
The DNA sequence selectivity of topoisomerase II (top2)-DNA cleavage complexes was examined for the human (top2α), yeast, and… Expand
Is this relevant?
1997
1997
Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
One approach to broadening the diversity of topoisomerase II-targeted anticancer agents is to generate novel compounds by… Expand
Is this relevant?
1995
1995
Azatoxin derivatives with potent and selective action on topoisomerase II.
Azatoxin was rationally designed as a DNA topoisomerase II (top2) inhibitor [Leteurtre et al., Cancer Res 52: 4478-4483, 1992… Expand
Is this relevant?
1994
1994
Effects of DNA methylation on topoisomerase I and II cleavage activities.
DNA methylation is deregulated during oncogenesis. Since several major anti-cancer drugs act on topoisomerases, we investigated… Expand
Is this relevant?
1994
1994
Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
BACKGROUND The cumulative cardiotoxicity of anthracyclines is thought to result from the generation of free radicals. New DNA… Expand
Is this relevant?
1993
1993
Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.
Azatoxin (NSC 640737) is a synthetic molecule that was rationally designed as a topoisomerase II inhibitor (Leteurtre et al… Expand
Is this relevant?
1992
1992
Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
Azatoxin [NSC 640737-M; 5.R,11aS-1H,6H,3-one-5,4,11,11a-tetrahydro-5-(3,5-dimethoxy-4-hydr oxyphenyl) oxazolo (3',4':1,6)pyrido… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 6
  • figure 5
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE